Research
Kyobo raises Hanmi MASH drug value; SK stresses global launches
Kyobo raises efinopegdutide's valuation from 1.4 trillion won to 1.5 trillion won and expects Phase 3 advancement. SK also argues for a sector rebound, emphasizing successful direct entry into global markets.